Earnings ·
Latipo raises $397M in IPO and reports $25.8M net loss as it advances onzotrigine into Phase 3
LTGOLatigo Biotherapeutics, Inc.
Latigo Biotherapeutics reported a net loss of $25.8 million for the quarter ended June 30, 2026, with R&D expenses at $21.2 million and G&A expenses rising to $4.6 million. The company completed an upsized IPO in August 2026, raising gross proceeds of $397.4 million, bringing total cash resources sufficient to fund operations into 2029. Clinical highlights include the publication of positive Phase 2 results for onzotrigine in acute pain in the New England Journal of Medicine and plans to initiate Phase 3 trials in bunionectomy patients later this year. Latigo also appointed Naomi Lowy, M.D., former FDA deputy director, as senior vice president of global regulatory affairs. Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines.